Illustration of amyloid plaques (orange) among brain cells
Science Photo Library/Alamy
In early July, the US Food and Drug Administration (FDA) approved a treatment called donanemab for people with early-stage Alzheimer’s disease. It is the second drug shown to slow the condition’s progression, and the third FDA-authorised medication that clears the amyloid proteins that accumulate in the brains of people with Alzheimer’s.
The FDA’s approval of three new drugs – donanemab, lecanemab and aducanumab – in just over three years has led some to declare a leap forward in Alzheimer’s disease treatment. Japan, South Korea, China,…
By Allen Kwabena Frimpong. Allen Kwabena Frimpong explores how the current creative industrial complex’s autocratic…
Everything is a new test for the New York Rangers as we wait and see…
BLOOM seeks to cut costs by helping financial institutions coordinate cross-border use of stablecoins and…
The husband-and-wife film-making team behind Wicker, Alex Huston Fischer and Eleanor Wilson, tell the BBC…
The school day may be over, but the miles keep adding up. Between the daily…
Photo: Adam Rose/Everett Collection Raise your glass, Disney ordered a new Glee revival series on…